Total amount: € 0,00
Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,014
Online ISSN 1827-1820
Cassano N., Colombo D. *, Vena G. A.
Università degli Studi di Bari Dipartimento di Clinica Medica, Immunologia e Malattie Infettive Unità di Dermatologia
IDI, IRCCS, Roma Istituto Dermopatico dell’Immacolata
* Novartis Farma S.p.A., Origgio (VA)
Several reports have confirmed the therapeutic usefulness of cyclosporin A for the treatment of psoriasis. After almost 15 years of experience, there are many data available as concerns administration, prevention and management of side effects. Considering both these premises and the common use in clinical practice, cyclosporin may be regarded as a first-line approach to psoriasis in eligible patients with severe forms of psoriasis. There is also an increasing trend towards the use of cyclosporine A in less severe forms of psoriasis, which are resistant to topical treatments and deteriorate significantly the quality of life. In these forms a low-dosage intermittent treatment should be preferable, even associated with topical agents if necessary. The use of intermittent treatment regimens offer many advantages, including cost reduction better compliance and better tolerability. Nevertheless, treatment with cyclosporin should be adapted to the single patient and can be influenced by many factors. On the whole, treatment with cyclosporin A is well-tolerated, if the generic recommendations and guidelines are observed. Side effects are commonly of mild intensity and can be controlled by dose adjustment. They fade away after treatment discontinuation. In this work, practical guidelines for use of cyclosporine A will be provided in accordance with recent literature reports and our personal experience, with particular emphasis on patient selection, therapeutic schemes, monitoring and management of side effects.